(reported by the Company)
No items found
THC`s objective is to be a leading, diversified, worldwide cannabis business focused on the manufacturing and distribution of hydroponics equipment, materials and nutrients; large-scale hydroponic greenhouse design and construction; and the development and delivery of medicinal cannabis.
We aim to capitalise on the surging global cannabis market, generating significant near term value through our strategic assets, rapidly expanding these core businesses in 2017 and beyond.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):||THC|
|Year of Commencement:|
Level 2, 131 Macquarie Street, Sydney, NSW, 2000. Australia.
|State:||New South Wales|
|Validated Problem Solver Engagements:||
No items found
|Current Period Rank:|
|Annual Rank (top 100 ranked companies only):||21|
Canada-based subsidiary, Crystal Mountain-Dragon Vision to start selling Nanolux Technology’s products in Canada
Partnered with BOL Pharma to supply medicinal cannabis
Appointed David Radford as chief executive officer
Entered its first partnership with Sinapse Pty Ltd as a key partner in its strategy to facilitate medicinal cannabis prescribing and dispensing in Australia
Secured a medicinal cannabis research licence (one of the first ASX-listed cannabis companies)
Announced joint venture with Phoenix Life Sciences Inc. to research, develop, produce, distribute, and sell medicinal cannabis products in Australia
Secured $8m in a share placement
NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking
|Type of capital raise:|